bionicjoe wrote: Oilminerdeluxe wrote: Those are three magic words!
What's magic about them when it comes with a major stipulation. The company keeps harping on 90 day results when the market is asking for more. We'll need to wait until July to see if patient 5 is still cancer free or experiences recurrence like the first 4 patients.
I'm not fond of these middle of the night ninja financial releases. IMO, it doesn't serve a company well to conduct their business that way. They had 3 months to release their year end financials so there is no excuse to do it on the last day and in the wee hours of the morning.
I figured their losses would be around $6 million and sure enough they didn't disappoint. It's interesting that after a couple of years of RW telling shareholders how important the American market was to sales of their lasers that those sales are down again. The small Canadian market still accounts for the bulk of their revenue and the company in this report offered no solution to increase American market share.
Cash on hand as of the end of 2017 was $253,902. I did a quick once over but I didn't see any reference to their cash burn. RW used to say it was in the $300,000 to $350,000 per quarter range so there can't be much left in the piggy bank now that the sp is out of warrant cashing range. They really need to clear that up and inform the market how they intend to pay for 2018 expenses? Dragging out the mystery isn't doing the sp any good.
Nothing really stands out in this report aside from the increased losses. I don't recall any mention of imminent trials in brain or lung cancer. They hinted at strategic partnerships or JVs but we don't know if that is realistic for the here and now or a hope for the future depending on the NMIBC clinical results? Maybe the Q1 2018 financials will shed some more light on the issues?